[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wenzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":168},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,37,68,96,121,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100585713","comparing-monofocal-iols-in-highly-myopic-cataract-patients-100585713",false,"NCT06905938","Comparing Monofocal IOLs in Highly Myopic Cataract Patients","Comparison of the Clinical Outcomes of Extended Depth of Focus Intraocular Lenses and Monofocal Intraocular Lenses in Patients With High Myopia Undergoing Cataract Surgery.","Inclusion Criteria:\n\n* 1: The patients are between 40 and 70 years old.\n\n  2: Ocular axis \\> 26mm\n\n  3: Able to understand, cooperate and complete all follow-up.\n\nExclusion Criteria:\n\n* 1: Moderate and severe dry eye\n\n  2: There is macular degeneration complicated by high myopia.\n\n  3: Combined with other ophthalmic diseases\n\n  4: Previous history of ophthalmic surgery.\n\n  5: There are intraoperative or postoperative complications.","ALL",{"count":18,"type":19},60,"ESTIMATED","OBSERVATIONAL","Comparison of Postoperative Outcomes in Patients with High Myopia Undergoing Cataract Surgery Implanted with Extended Depth of Focus Intraocular Lens (ICB00) and Monofocal Intraocular Lens (ZCB00)",[23],"Cataract","NOT_YET_RECRUITING","2025-03-28",{"date":27,"type":28},"2025-04-02","ACTUAL",{"date":30,"type":19},"2025-04-01",{"date":32,"type":19},"2026-05-30",{"name":34,"class":35},"Wenzhou Medical University","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":36},"100264808","phase-3-the-efficacy-and-safety-of-combined-therapy-with-red-yeast-rice-and-low-dose-statincomparing-with-standardized-statin-100264808","NCT02726555","The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin","Comparison Between Combined Therapy With Red Yeast Rice and Low-dose Statin and Standardized Statin: a Single-center, Non-inferiority, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients with established mild atherosclerotic cardiovascular disease, defined as coronary and\u002For carotid and\u002For peripheral artery lesions \\\u003C40% lumen diameter stenosis, diagnosed by coronary angiography and carotid and\u002For peripheral artery ultrasound respectively, together with LDL cholesterol level \\> 70 mg\u002FdL (1.80 mmol\u002FL).\n2. Female patients must be postmenopausal as defined by no menstruation for at least 12 months, or surgically sterilized for at least three months prior to beginning the study, or have a negative pregnancy test and agree to avoid pregnancy during the study and one month after the end of the study by using two reliable methods of contraception.\n3. Patients must have been informed of all aspects of the study and signed an informed consent form before any study-related activities.\n4. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\nPatients who have met all the above inclusion criteria will be screened for the following exclusion criteria.\n\n1. Patients who have been taken lipid-lowering medications including statins or red yeast rice products during the 4 weeks prior to the screening visit.\n2. Documented history of myocardial infarction (MI), unstable angina leading to hospitalization, uncontrolled cardiac arrhythmia, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG), carotid surgery or stenting, cerebrovascular accident, transient ischemic attack, endovascular procedure or surgical intervention for peripheral vascular disease.\n3. Planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during the study.\n4. History of New York Heart Association Class III or IV heart failure within the past 12 months.\n5. Known history of hemorrhagic stroke.\n6. Patients with uncontrolled hypertension at the screening visit. Patients on stable antihypertensive medication may be enrolled provided that the medications and dosage remain stable throughout the study.\n7. Cardiovascular surgery or major operations within 6 months prior to screening visit.\n8. Patients who are taking anticoagulants except aspirin at \\\u003C 325 mg\u002Fday.\n9. Patients with liver dysfunction as indicated by a serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level of \\> 1.5-times of upper limit of normal (ULN) range, or clinical symptoms.\n10. Patients with elevated creatine phosphokinase level (above Upper Limit of Normal range).\n11. Patients with renal dysfunction as indicated by a serum creatinine level above ULN range, or clinical symptoms.\n12. Patients with gastric or peptic ulcer within 3 months prior to screening visit.\n13. Patients with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, or primary biliary cirrhosis. Patients on thyroid replacement therapy at stable doses may be enrolled if clinically euthyroid.\n14. Patients with clinically relevant illness within 4 weeks prior to screening visit that may interfere with the conduct of this study.\n15. Patients with a history of alcohol or narcotic substance abuse within two years prior to screening visit.\n16. Patients with hypersensitivity to lipid-lowering agents.\n17. Patients who have taken another investigational drug within 4 weeks prior to screening visit.\n18. Patients with uncontrolled metabolic or endocrine disease knowing to influence lipid values.\n19. Patients who are known to be HIV positive.\n20. Patients who have a history or presence of active malignancy (other than non-melanoma skin cancer) or clinically significant psychiatric, neurological, respiratory, hematological, or other conditions that in the opinion of investigators might interfere with or contraindicate participation of the patients in this study.","20 Years","80 Years",{"count":47,"type":19},240,"INTERVENTIONAL",[50],"PHASE3","Double-dose statin regimen achieves merely 6% of decrease in low-density lipoprotein cholesterol (LDL-C) levels, whereas the risk of side effects increased largely. The investigators' previous pilot study (NCT01686451) has suggested that red yeast rice was of similar lipid-lowering efficacy while was associated with less fatigue than statins. The purpose of this study is to evaluate the efficacy and safety of combined therapy with red yeast rice and low-dose atorvastatin in persons with mild atherosclerotic cardiovascular disease and who qualified for statin therapy according to national guidelines.",[53,54],"Dyslipidemia","Atherosclerosis",[56,57,58],"Red yeast rice","Atorvastatin","Mild cardiovascular disease","RECRUITING","2024-08-04",{"date":62,"type":28},"2024-08-06",{"date":64,"type":28},"2015-11",{"date":66,"type":19},"2026-05",{"name":34,"class":35},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":36},"100294712","the-effects-of-anesthesia-type-on-the-prognosis-of-hip-fracture-surgery-on-elderly-patients-100294712","NCT03116490","The Effects of Anesthesia Type on the Prognosis of Hip Fracture Surgery on Elderly Patients","The Comparative Effects of Regional or General Anesthesia on the Prognosis of Hip Fracture Surgery on Elderly Patients","Inclusion Criteria:\n\n* Patients with hip fracture;\n* Need surgery;\n* Anesthesia type is regional anesthesia or general anesthesia;\n* Age≥60 years.\n\nExclusion Criteria:\n\n* Choosing conservative treatment;\n* Other types of anesthesia or without anesthesia.","60 Years",{"count":77,"type":19},600,"The aim of this study is to figure out whether anesthesia type have an influence on the prognosis of hip fracture surgery.30-day mortality and morbidity after the surgery are our main observational index,and according to literature and our experience,regional anesthesia may have a better prognosis after hip fracture surgery compared with general anesthesia.",[80,81],"Postoperative Complications","Postoperative Mortality",[83,84,85,86,87],"morbidity","mortality","hip fracture","anesthesia type","POSSUM","2024-07-23",{"date":90,"type":28},"2024-07-24",{"date":92,"type":19},"2026-01-16",{"date":94,"type":19},"2028-12",{"name":34,"class":35},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":36},"100308762","accuracy-of-corneal-astigmatism-in-different-region-modes-100308762","NCT03299530","Accuracy of Corneal Astigmatism in Different Region Modes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.\n* Best corrected visual acuity ≥ 0.66 (20\u002F30 Snellen)\n\nExclusion Criteria:\n\n* Corneal diseases or severe irregular astigmatism (e.g., pterygium, keratoconus), existence of corneal opacification;\n* Ocular disease which may affect visual acuity (e.g., glaucoma, uveitis, retinal disease, pathologic myopia);\n* History of ocular surgery or ocular trauma before this cataract surgery;\n* Decentration of IOL \\> 0.3mm or tilt \\> 5°\n* Implantation of multifocal IOL\n* history of wearing of rigid contact lens within the past 4 weeks or soft contact lens within 1 week;","18 Years",{"count":104,"type":19},70,"To analyze the difference between measured total corneal astigmatism and actual corneal astigmatism under different region modes and optimize the region setting.",[107,108],"Astigmatism","Cornea",[110,111,112,113],"Corneal Astigmatism","Scheimpflug","pupil size","Toric","2024-07-22",{"date":88,"type":28},{"date":117,"type":28},"2017-10-10",{"date":119,"type":19},"2026-10-28",{"name":34,"class":35},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":16,"minAge":102,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":48,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100290306","safety-and-efficacy-study-of-a-viscoelastic-free-method-for-implantable-collamer-lens-icl-implantation-100290306","NCT03059043","Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation","Prospective, Multicenter,Randomized Clinical Investigation of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation to Treat High Myopia: A Pilot Study","Inclusion Criteria:\n\n* Documented stable refraction for at least 1 year(within 0.5D)\n* Best spectacle-corrected visual acuity (BCVA) of 20\u002F40 or better\n* Clear central cornea\n* -0.5D to -18.0D of myopic refractive error\n* Normal anterior chamber depth at least 2.8 mm to endothelium\n* Endothelial cell density (ECD) more than 2000 cell\u002Fmm2\n* Pupil diameter smaller than 7.0 mm under mesopic condition\n* Discontinued 3 weeks for hard contact lens and 1 week for soft contact lens wear\n\nExclusion Criteria:\n\n* Preexisting ocular diseases or conditions other than myopia, evidence of progressive or acute ocular disease\n* Evidence of connective tissue disease or other systemic diseases that may confound the results of the study;\n* Narrow angle of anterior chamber\n* Pregnant, lactating, or planning to become pregnant during the course of the trial",true,"45 Years",{"count":18,"type":19},[132],"NA","This study evaluates the safety and efficacy of a viscoelastic-free method for Implantable Collamer Lens(ICL) implantation to treat high myopia. The subjects undergo randomization of ICL implantation using the viscoelastic-free method on one eye and undergoing standard method on the other one. The post-operative data are collected for analysis.",[135],"Myopia",[137,138],"Phakic Intraocular Lenses","viscoelastic",{"date":88,"type":28},{"date":141,"type":28},"2018-11-16",{"date":143,"type":19},"2026-06-22",{"name":34,"class":35},5,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":45,"enrollmentInfo":154,"targetDuration":4,"studyType":48,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":36},"100261164","comparison-of-outcomes-with-multifocal-intraocular-lenses-100261164","NCT02678962","Comparison of Outcomes With Multifocal Intraocular Lenses","COMIL","Inclusion Criteria:\n\n* Age from 40 to 80 years old, either gender;\n* Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;\n* Willing to undergo second eye surgery within 7 days after first eye surgery;\n* The potential postoperative visual acuity of 20\u002F40 or better in both eyes;\n* Preoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation;\n* Capability to understand the informed consent and willing and able to attend study\n\nExclusion Criteria:\n\n* Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;\n* Preexisting systemic diseases or conditions that may confound the results of the study;\n* Previous ocular surgery history or ocular trauma that may confound the results of the study;\n* Require combined surgery that may confound the results of the study;\n* Previous participation in other clinical trial within 30 days of this study start;\n* Systemic or ocular medications that may confound the outcome of the intervention\n* Pregnant, lactating, or planning to become pregnant during the course of the trial;","40 Years",{"count":155,"type":19},90,[132],"The purpose of this study is to compare and evaluate the clinical outcomes of 6 kinds of Multifocal Intraocular Lenses: SN6AD1, SBL-3, LS-313 MF30, AT LISA tri 839 MP, ART, LS-313 MF30T.",[23],[160,161],"Multifocal Intraocular Lenses","bilateral implantation",{"date":88,"type":28},{"date":164,"type":4},"2016-02",{"date":166,"type":19},"2026-06",{"name":34,"class":35},""]